04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form DEF 14A | |
04/26/2024
1:33 PM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form ARS | |
04/26/2024
1:34 PM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form DEFA14A | |
04/22/2024
3:44 PM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/02/2024
2:43 PM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/14/2024
7:51 PM | Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/14/2024
7:53 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
03/14/2024
7:54 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/07/2024
3:29 PM | Babler Martin (Reporting)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
5:20 PM | Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
Smith Sean Michael (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
6:30 AM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/20/2024
3:16 PM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/14/2024
5:05 PM | EcoR1 Capital, LLC (Filed by)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
| Form SC 13G | |
02/14/2024
8:19 AM | Lynx1 Capital Management LP (Filed by)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
| Form SC 13G/A | |
02/09/2024
3:35 PM | Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
SIMPSON TODD E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/18/2024
5:56 PM | Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Noonberg Sarah B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:58 PM | Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
PALEKAR ROHAN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
6:01 PM | Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Woods Robert Keith (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:45 PM | Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
01/18/2024
5:48 PM | Jordan Julie (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:51 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
5:53 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
6:11 AM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/26/2023
5:04 PM | Freedland Cory S. (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:05 PM | Cobb Stuart (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:10 PM | BAFFI ROBERT (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:10 PM | Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
Woods Robert Keith (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:12 PM | McMinn Rachel (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/26/2023
5:16 PM | Cvijic Christine Mikail (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
12/20/2023
5:43 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neurogene Inc. (Issuer)
Neurogene Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2023
4:24 PM | BAKER BROS. ADVISORS LP (Filed by)
Neurogene Inc. (Subject)
Neurogene Inc. (Subject)
Neurogene (Subject)
| Form SC 13D/A | |
12/19/2023
6:31 AM | Neurogene Inc. (Filer)
Neurogene Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2023
3:21 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2023
3:24 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
| Form 425 | |
12/04/2023
4:10 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/04/2023
4:14 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
| Form 425 | |
11/13/2023
11:15 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form EFFECT | |
11/08/2023
1:34 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form S-4/A | |
10/18/2023
3:09 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form S-4/A | |
10/10/2023
3:42 PM | BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
| Form SC 13D/A | |
10/10/2023
3:22 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neoleukin Therapeutics, Inc. (Issuer)
Neoleukin Therapeutics, Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
This AI Trade Machine Made 1,729%* (With 89% Wins) (Ad) This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate…
And a cumulative gain of 1729%.
How does it all work? Click Here To Get Your Free Copy |
10/05/2023
11:50 AM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
| Form 425 | |
09/28/2023
3:28 PM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form S-4/A | |
09/22/2023
7:03 AM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/17/2023
4:08 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Neoleukin Therapeutics, Inc. (Issuer)
Neoleukin Therapeutics, Inc. (Issuer)
Neurogene (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/17/2023
4:12 PM | BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
| Form SC 13D/A | |
07/27/2023
4:15 PM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
Redmile Group, LLC (Filed by)
| Form SC 13D | |
07/19/2023
4:28 PM | BAKER BROS. ADVISORS LP (Filed by)
Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
| Form SC 13D/A | |
07/18/2023
7:34 AM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2023
7:37 AM | Neoleukin Therapeutics, Inc. (Subject)
Neoleukin Therapeutics, Inc. (Subject)
Neurogene (Subject)
| Form 425 | |
06/12/2023
11:57 AM | Neoleukin Therapeutics, Inc. (Filer)
Neoleukin Therapeutics, Inc. (Filer)
Neurogene (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
